Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
genfit
5
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
gilead sciences
indiana blog main
indiana top stories
national
nonalcoholic steatohepatitis
pfizer
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
autoimmune diseases
bayer
biotech
bristol-myers squibb
cell therapy
clinical trials
deals
investing
merck
What
bio
roundup
drug
amid
bombast
cancer
caught
coronavirus
debate
develop
discussion
efforts
meso’s
miss
nash
new
pandemic
pfizer’s
presidential
promise
response
tuesday’s
vaccine
viewers
aducanumab
advantages
alzheimer’s
amyloid
angst
approved
bagged
bar
billions
biogen
biogen’s
brammer
brings
data
disease
effects
Language
unset
Current search:
genfit
×
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
